Concise synthesis of capuramycin

Organic Letters

Volumn 11, Issue 11, 2009, Pages 2393-2396

  Kurosu, Michio ^a   Li, Kai ^a   Crick, Dean C ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; CAPURAMYCIN; TUBERCULOSTATIC AGENT;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; MICROBIOLOGICAL EXAMINATION; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

AMINOGLYCOSIDES; ANTITUBERCULAR AGENTS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 66149190559     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol900458w     Document Type: Article

References (53)

1. Rouhi, A. M. Chem. Eng. News 1999, 77, 52.
2. DOTS (directly observed therapy shortcourse therapy) uses a battery of drugs in a prescribed order to eradicate tuberculosis and avoid the creation of drug-resistant strains of the disease.
3. Cole, S. T.; Alzari, P. M. Science 2005, 14, 214.
4. Stover, C. K.; Warrener, P.; van Devater, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Kreiswirth, B. N.; Barry, C. E.; Baker, W. R. Nature (London) 2000, 405, 962.
5. Godfrey-Faussett, P. AIDS 2003, 17, 1079.
6. Cohen, J. Science 2004, 306, 1872.
7. Higashi, Y.; Strominger, J. L.; Sweeley, C. C. J. Biol. Chem.1970, 245, 3697.
8. van Heijenoort, J. Cell. Mol. Life Sci. 1998, 54, 300.
9. van Heijenoort, J. Glycobiology 2001, 11, 25R.
10. Kimura, K.; Bugg, T. D. H. Nat. Prod. Pep. 2003, 20, 252.
11. Taha, M. O.; Atallah, N.; Al-Bakri, A. G.; Pradis-Bleau, C.; Zalloum, H.; Yonis, K. S.; Levesque, P. C. Bioorg. Med. Chem. 2008, 16, 1218.
12. Lovering, A. L.; de Castro, L. H.; Lim, D.; Strynadka, N. J. Science2007, 315, 1402.
13. Wright, G. D. Science 2007, 315, 1373.
14. Singh, S. B.; Barrett, J. F. Biochem. Pharmacol. 2006, 71, 1006.
15. Antane, S.; Caufield, C. E.; Hu, W.; Keeney, D.; Labthavikul, P.; Morris, K.; Naughton, S. M.; Petersen, P. J.; Rasmussenm, B. A.; Singh, G.; Yang, Y. Bioorg. Med. Chem. 2006, 16, 176.
16. Helm, J. S.; Hu, Y.; Chen, L.; Gross, B.; Walker, S. J. Am. Chem. Soc. 2003, 125, 11168.
17. Cudic, P.; Behenna, D. C.; Yu, M. K.; Kruger, R. G.; Szwczuk, L. M.; McCafferty, D. G. Bioorg. Med. Chem. Lett. 2001, 11, 3107.
18. Ha, S.; Chang, E.; Lo, M.-C.; Park, P.; Ge, M.; Walker, S. J. Am. Chem. Soc. 1999, 121, 8415.
19. Timothy, D. H.; Lloyd, A. J.; Roper, D. I. Infect. Disor.: Drug Targets 2006, 6, 85.
20. Dini, C. Curr. Top. Med. Chem. 2005, 5, 1221.
21. Uridat, E.; Zhang, J.; Aszodi, J. Bioorg. Med. Chem. Lett. 2002, 12, 1209.
22. Dini, C.; Drochon, N.; Feteanu, S.; Guillot, J. C.; Peixoto, C.; Aszodi, J. Bioorg. Med. Chem. Lett. 2001, 11, 529.
23. Koga, T.; Fukuoka, T.; Harasaki, T.; Inoue, H.; Hotoda, H.; Kakuta, M.; Muramatsu, Y.; Yamamura, N.; Hoshi, M.; Hirota, T. J. Antimicro. Chemother. 2004, 54, 755.
24. Yamaguchi, H.; Sato, S.; Yoshida, S.; Takeda, K.; Itoh, M.; Seto, H.; Otake, N. J. Antibiot. 1986, 39, 1047.
25. Reddy, V. M.; Einck, L.; Nacy, C A. Antimicro. Agents Chemther.2008, 52, 719.
26. Knapp, S.; Nandan, S. R. J. Org. Chem. 1994, 59, 281.
27. Uncharacterizable byproducts were isolated in addition to the overdeacetylation products.
28. Ito, T.; Ueda, S.; Takaku, H. J. Org. Chem. 1986, 51, 931.
29. Ranganathan, R. S.; Jones, G. H.; Moffatt, J. G. J. Org. Chem.1974, 39, 290.
30. Pfitzner, K. E.; Moffatt, J. G. J. Am. Chem. Soc. 1963, 85, 3027.
31. North, M. Tetrahedron: Asymmetry 2003, 14, 147, and references therein.
32. Krueger, C. A.; Kuntz, K. W.; Dzierba, C. D.; Wirschun, W. G.; Gleason, J. D.; Snapper, M. L.; Hoveyda, A. H. J. Am. Chem. Soc. 1999, 121, 4284.
33. Mori, M.; Imma, H.; Nakai, T. Tetrahedron Lett. 1997, 38, 6229.
34. The stereochemistry of 5a was established by the advanced Mosher method, see Supporting Information.
35. Ti(OiPr)4 is known to form Ti-oxo species such as [Ti7O4](OR)20, [Ti8O6](OR)20, and [Ti12O16](OR)16 with trace amount of water through Ti(OiPr)3(OH), see: Hubert-Pfalzgraf, L. G. J. Mater. Chem. 2004, 14, 3113.
36. Jones, A. C.; Leedham, T. J.; Wright, P. J.; Crosbie, M. J.; Fleeting, K. A.; Otway, D. J.; O'Brien, P.; Pemble, M. E. J. Mater. Chem. 1998, 8, 1773.
37. Kurosu, M.; Lorca, M. Synlett 2005, 7, 1109.
38. We are currently investigating a chiral reagent which promotes the reaction of 4 to 5a with high yield and high selectivity.
39. Addition of pyridine was indispensable for successful inversion of the C5′-stereocenter of 5b with ClCH2CO2H.
40. La'za'r, L.; Bajza, I.; Jakab, Z.; Lipta'k, A. Synlett 2005, 14, 2242.
41. Yeeneman, G. H.; van Leeuwen, S. H.; van Boom, J. H. Tetrahedron Lett. 1990, 31, 1331.
42. The orthoester 7 shows a characteristic chemical shift of 1.78 ppm (CH3) in the 1H NMR spectrum.
43. Due to the fact that all triflate ion associated glycosylations with 6(entries 1-3) yielded a mixture of R-and-mannosides, the mannosyl carbenium ion generated directly from 6 or through the orthoester 7 would be transformed to the R-glycosyl triflate which furnishes the undesired-mannoside 8b.
44. The formation of orthoesters had previously been reported with a number of different glycosyl donors which react through an oxonium ion intermediate and contain a C2-acetyl group, see: Harreus, A. H.; Kunz, H. Liebigs Ann. Chem 1986, 717.
45. Fukase, K.; Hasuoka, A.; Kinoshita, I.; Aoki, Y.; Kusumoto, S. Tetrahedron 1995, 51, 4923.
46. Kaeothip, S.; Pornsuriyasak, P.; Demchenko, A. V. Tetrahedron Lett. 2008, 49, 1542.
47. Winstein, S.; Clippinger, E.; Fainberg, A. H.; Heck, R.; , G. C.; Robinson, G. C. J. Am. Chem. Soc. 1956, 78, 328.
48. The isolated orthoester 7 could be rearranged to 8a by the treatment with HBF4·OEt2 compex in CH2Cl2.
49. Ghaffar, T.; Parkins, A. W. Tetrahedron Lett. 1995, 36, 8657.
50. Deprotection of the BOM-protected 13 under these conditions was ∼40% yield.
51. Orita, A.; Hamada, Y.; Nakano, T.; Toyoshima, S.; Otera, J. Chem.-Eur. J. 2001, 7, 3321.
52. Parikh, J. R.; Doering, W. E. J. Am. Chem. Soc. 1967, 89, 5505.
53. See Supporting Informataion.